Survival of Motor Neuron 2, Telomeric - SMN2 is a paralog of SMN1 that encodes the Survival of Motor Neuron protein, critical for spliceosomal function and motor neuron survival.
| Property | Value |
|---|---|
| Gene Symbol | SMN2 |
| Full Name | Survival of Motor Neuron 2, Telomeric |
| Chromosomal Location | 5q13.2 (Chr5: 70,287,588-70,345,635) |
| NCBI Gene ID | 6609 |
| OMIM | 601627 |
| Ensembl ID | ENSG00000120247 |
| UniProt | Q16637 |
| Protein Name | Survival of Motor Neuron protein |
| Protein Length | 294 amino acids |
| Molecular Weight | ~32 kDa |
The SMN2 gene is a paralog of SMN1 located on chromosome 5q13.2. While SMN1 is the primary source of functional SMN protein, SMN2 serves as a disease modifier in spinal muscular atrophy (SMA). The SMN2 gene differs from SMN1 by a critical C→T transition at position 6 of exon 7, which causes exon 7 skipping during splicing, resulting in the production of a truncated and unstable protein (SMNΔ7) instead of full-length functional SMN protein[1].
Despite producing mostly defective protein, SMN2 copy number significantly influences SMA severity - this discovery became the foundation for all SMA therapeutics that work by enhancing SMN2 splicing or expression. Understanding SMN2 biology is essential for developing new treatments for SMA and potentially other neurodegenerative diseases[2].
SMN2 encodes the Survival of Motor Neuron (SMN) protein, which is essential for the assembly of the spliceosomal small nuclear ribonucleoproteins (snRNPs). The SMN complex plays a critical role in pre-mRNA splicing by facilitating the biogenesis of U1, U2, U4, and U5 snRNPs[3].
The key difference between SMN1 and SMN2 is the splicing of exon 7:
| Tissue | Expression Level |
|---|---|
| Spinal cord | Highest |
| Brain | High |
| Skeletal muscle | High |
| Heart | Moderate |
| Liver | Low-Moderate |
| Kidney | Low |
SMA is an autosomal recessive neuromuscular disorder caused by deletion or mutation of SMN1, with SMN2 serving as the major disease modifier[4].
| SMN2 Copies | Expected Phenotype |
|---|---|
| 0 | No functional SMN - embryonic lethal |
| 1 | Severe SMA (Type 0) - neonatal death |
| 2 | Severe SMA (Type I) - onset before 6 months |
| 3 | Intermediate (Type II/III) - onset 6-18 months |
| 4+ | Mild/Adult-onset (Type III/IV) - later onset |
SMN deficiency leads to:
Recent research suggests SMN deficiency may contribute to ALS pathogenesis[5]:
All three FDA-approved SMA therapies target SMN2 to increase functional SMN protein production[6]:
| Drug | Target | Mechanism |
|---|---|---|
| Nusinersen | Intronic splicing silencer (ISS) | Blocks ISS-N1, promotes exon 7 inclusion |
| Risdiplam | SMN2 pre-mRNA | Stabilizes interaction between splice enhancers |
| Gene therapy | SMN1 gene replacement | Delivers functional SMN1 via AAV9 |
The study of Smn2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lefebvre S, et al. "Identification and characterization of a spinal muscular atrophy-determining gene." Cell. 1995. ↩︎
Lorson CL, et al. "A single nucleotide in the SMN gene regulates splicing." Proc Natl Acad Sci. 1999. ↩︎
Pellizzoni L, et al. "Essential role for the SMN complex in the assembly of snRNPs." Curr Opin Cell Biol. 2002. ↩︎
Finkel RS, et al. "Nusinersen in infants with SMA." N Engl J Med. 2017. ↩︎
Mendell JR, et al. "Gene therapy for SMA." N Engl J Med. 2017. ↩︎
Baranello G, et al. "Risdiplam in Type 1 SMA." N Engl J Med. 2021. ↩︎